# Rituximab in Patients With Acute Rheumatic Fever

> **NCT05682196** · PHASE2 · SUSPENDED · sponsor: **African Academy of Methodology and Statistics** · enrollment: 234 (estimated)

## Conditions studied

- Rheumatic Heart Disease in Children

## Interventions

- **DRUG:** Rituximab added to standard of care treatment
- **DRUG:** standard of care treatment alone

## Key facts

- **NCT ID:** NCT05682196
- **Lead sponsor:** African Academy of Methodology and Statistics
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-01-05
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-02-01
- **Target enrollment:** 234 (ESTIMATED)
- **Why stopped:** ethical controversy
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05682196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05682196, "Rituximab in Patients With Acute Rheumatic Fever". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05682196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*